• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by LianBio

    LianBio Announces Voluntarily Delisting from Nasdaq
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Completion of Strategic Review
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Departure of Chief Financial Officer
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Departure of Chief Executive Officer
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio to Participate in Upcoming Investor Conferences
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Promotes Pascal Qian to Chief Commercial Officer
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Announces President and Chief Strategy Officer Departure
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
    From LianBio
    Via GlobeNewswire
    Tickers LIAN
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.